Celebrating the new era of oncology
The annual ESMO Congress returns to be an onsite event after two years of COVID-19 pandemic, offering attendees opportunities to share knowledge on how to integrate molecular and digital tools into oncology
Gender equity in oncology – are we nearer to close the gender gap?
At the ESMO Women for Oncology Forum, international experts will discuss the latest data on female representation in the field
The effect of ‘publish or perish’ on young academic oncologists
Oncologists at an early stage in their career may fall into the trap of predatory journals whilst seeking to publish their research
Practice-changing treatments in GU cancers continue to evolve
Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
More women in leadership roles are key to patient-centred medicine
According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials
Cancer Research
Colorectal cancer: guided by the gut?
Recent evidence suggests a role of the microbiome in cancer pathogenesis and as a potential therapeutic target, but it is still early days
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy